GRK2 GRK5 Inhibitor Compounds for Heart Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GRK inhibitors for treating heart disease lack high potency, selectivity, and good pharmacokinetic properties, leading to ineffective treatment and prevention of cardiac conditions such as heart failure and hypertension.
Innovation Solution
Development of compounds with specific structures, such as those described in Formula (I), which selectively inhibit GRK2 and GRK5 with high potency and selectivity, improving their inhibition over other GRK family members, thereby addressing the limitations of existing inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current GRK inhibitors are used for treating heart disease, then treatment is provided, but they lack high potency and selectivity leading to ineffective treatment
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structure parameters of GRK inhibitors. The compounds feature specific structural elements including a piperidine ring, fluorophenyl group, and various substituents (R1-R6) that can be varied to optimize potency. The molecular weight range (300-700 Da) and specific functional groups are tuned to achieve high nanomolar to low micromolar potency while maintaining selectivity for GRK2 and GRK5 over other kinases
Solution Approach 2:
The patent implements local quality by introducing specific functional groups at particular positions in the molecular structure. The piperidine ring nitrogen can be substituted with specific groups, the fluorophenyl group is positioned at a specific location, and R1-R6 substituents are placed to interact with specific residues in the GRK2/GRK5 binding pocket. This localized optimization of structural features enhances binding affinity and selectivity for the target kinases
2Reliability
If current GRK inhibitors are used, then treatment is provided, but they lack selectivity over other GRK family members
Solution Approach 1:
The patent implements local quality by introducing specific functional groups at particular positions in the molecular structure. The piperidine ring nitrogen can be substituted with specific groups, the fluorophenyl group is positioned at a specific location, and R1-R6 substituents are placed to interact with specific residues in the GRK2/GRK5 binding pocket. This localized optimization of structural features enhances binding affinity and selectivity for the target kinases
Solution Approach 2:
The patent uses the unique structural features of the inhibitor compounds as intermediaries that specifically bridge the gap between the drug molecule and the GRK2/GRK5 active site. The piperidine ring and fluorophenyl group act as mediating structures that facilitate selective binding through specific molecular interactions with GRK2/GRK5 while excluding other GRK family members, thereby achieving high selectivity
3Reliability
If current GRK inhibitors are used, then treatment is provided, but they lack good pharmacokinetic properties
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structure parameters of GRK inhibitors. The compounds feature specific structural elements including a piperidine ring, fluorophenyl group, and various substituents (R1-R6) that can be varied to optimize potency. The molecular weight range (300-700 Da) and specific functional groups are tuned to achieve high nanomolar to low micromolar potency while maintaining selectivity for GRK2 and GRK5 over other kinases
Data Source
AI summary
Disclosed herein are novel GRK inhibitors and methods for their use in treating or preventing heart disease, such as cardiac failure, cardiac hypertrophy, and hypertension. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof, wherein the substituents are as described.